References
- National Heart, Lung, and Blood Institute / World Health Organization Workshop Report. Global initiative for asthma: global strategy for asthma management and prevention. NIH Publication No. 95–3659. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD 1995
- National Asthma Education and Prevention Program. Expert panel report 2. Guidelines for the diagnosis and management of asthma. NIH Publication No. 97–4051. National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD 1997
- Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S. Comparison of a beta2-agonist, terbuta-line, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388
- Van Essen-Zandvliet E E, Hughes M D, Waalkens H J, Divverman E J, Pocock S J, Kerrebijn K F. Effects of 22 months of treatment with inhaled corticosteroids and/or beta2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Nonspecific Lung Disease Study Group. Am Rev Respir Dis 1992; 146: 547
- Djukanovic R, Wilson J W, Britten K M, Wilson S J, Walls A F, Roche W R. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 245: 669
- Lorentzson S, Boe J, Eriksson G, Persson G. Use of inhaled corticosteroids in patients with mild asthma. Thorax 1990; 45: 733
- D'Alonzo G E, Nathan R A, Henochowicz S, Morris R J, Ratner P, Rennard S. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA 1994; 271: 1412
- Britton M G, Earnshaw J S, Palmer J BD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062
- Pearlman D S, Chervinsky P, LaForce C, Seltzer J M, Southern D L, Kemp J P. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327: 1420
- Greening A P, Ind P W, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219
- Woolcock A, Lundback B, Ringdal N, Jacques L A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481
- Crapo R O, Morris A H, Gardner R M. Reference spiro-metric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659
- American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202
- Butcher P R, Vardey C J, Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol 1991; 104: 672
- Bolton P B, Lefevre P, McDonald D M. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 1997; 255: 1428
- Boulet L-P, Turcotte H, Boutet M, Dube J, Gagnon M, Laviolette M. Influence of salmeterol on chronic and allergen-induced airway inflammation in mild allergic asthma: a pilot study. Curr Ther Res 1997; 58: 240
- Twentyman O P, Finnerty J P, Harris A, Palmer J, Holgate S T. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336: 1338
- Pederson B, Dahl R, Larsen B B, Venge P. The effect of salmeterol on the early- and late-phase reaction to bronchial challenge and post-challenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein and serum eosinophil protein X. Allergy 1993; 48: 377
- Oddera S, Silvestri M, Testi R, Rossi G A. Salmeterol enhances in vitro the inhibitory effects of dexametha-sone on allergen-induced T-lymphocyte activation, partially suppressing the release of GM-CSF and TNF-alpha. Eur Resp J 1994; 2110, Suppl 18
- Barnes P J. Molecular mechanisms of steroid action in asthma. J Allergy Clin Immunol 1996; 97: 159
- Booth H, Fishwick K, Harkawat R, Devereaux G, Hendrick D J, Walter E H. Changes in methacholine-induced bronchoconstriction with the long-acting beta2-agonist salmeterol in mild to moderate asthmatic patients. Thorax 1993; 48: 121
- Arledge T E, Liddle R, Stahl E, Rossing T H. Salmeterol does not cause tolerance during long-term asthma therapy. J Allergy Clin Immunol 1996; 98: 1116
- Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients: an evaluation of asthma symptoms and the possible development of tachyphylaxis. Am Rev Respir Dis 1990; 142: 571